Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05093205 · ClinicalTrials.gov registry record · Phase 1
Study TO Evaluate THE Effect OF PF-06882961 ON Single Dose Atorvastatin, Medazolam AND Oralcontraceptive Pharmacokinetics IN Healthy Adult Participants
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT05093205: Completed Phase 1 study, sponsored by Pfizer.
NCT05093205 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 35 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05093205, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the effect of PF-06882961, administered at 2 steady-state dose levels, on the PK of single doses of atorvastatin (20 mg) or midazolam (5 mg), administered separately, in healthy adult male and female participants (Part A), or an OC in healthy PM female participants (Part B).
Primary Outcome
Atorvastatin was given on Day 1 in Periods 1, 4 and 7 of Part A and blood samples were collected for atorvastatin pharmacokinetic (PK) at the preset time points described in the Time Frame. AUCinf calculated area under the plasma concentration-time profile from time 0 extrapolated to infinite time.
Interventions
- DRUG Midazolam
- DRUG Atorvastatin
- DRUG PF-06882961
- DRUG Levonorgestrel & Ethinyl Estradiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2021-10-25 |
| Est. Completion | 2022-07-06 |
| Phase | Phase 1 |
What the finished NCT05093205 record still lists
NCT05093205 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 4 interventions - of which Midazolam is the first listed.
NCT05093205 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05093205 about?
NCT05093205 is a clinical study titled "Study TO Evaluate THE Effect OF PF-06882961 ON Single Dose Atorvastatin, Medazolam AND Oralcontraceptive Pharmacokinetics IN Healthy Adult Participants". The purpose of this study is to characterize the effect of PF-06882961, administered at 2 steady-state dose levels, on the PK of single doses of atorvastatin (20 mg) or midazolam (5 mg), administered separately, in healthy adult male and female participants (Part A), or an OC in healthy PM female pa...
What is the current status of trial NCT05093205?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2021-10-25. Estimated completion is 2022-07-06.
What interventions are being tested in trial NCT05093205?
The interventions under investigation include: Midazolam (DRUG), Atorvastatin (DRUG), PF-06882961 (DRUG), Levonorgestrel & Ethinyl Estradiol (DRUG).
Who is sponsoring clinical trial NCT05093205?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05093205's enrollment target sits among peer trials
35 1258th of 2000 higher than 728 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI